All Updates

All Updates

icon
Filter
Funding
Partnerships
Recursion secures USD 50 million PIPE investment and partnership from NVIDIA
AI Drug Discovery
Jul 12, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Jul 12, 2023

Recursion secures USD 50 million PIPE investment and partnership from NVIDIA

Funding
Partnerships

  • Utah-based AI biotechnology company Recursion Pharmaceuticals has secured USD 50 million as private investment in public equity (PIPE) from NVIDIA to accelerate the development of AI models for drug discovery. In relation to this, Recursion will also partner with NVIDIA to leverage the latter's cloud services.

  • The funding and partnership will facilitate the training of AI foundation models for drug discovery by leveraging Recursion’s proprietary biological and chemical dataset—with over 23 petabytes and three trillion searchable gene and compound relationships—and NVIDIA’s DGX cloud. NVIDIA will also offer its AI stack and full-stack computing expertise to Recursion. 

  • NVIDIA is expecting to commercially license or release the AI models on its cloud service for generative AI in drug discovery BioNeMo, while Recursion plans to leverage the cloud service to advance its internal therapeutic pipeline and of its partners. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.